nach oben

Erschienen in:

20.09.2019 | Original Article

Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer

verfasst von: Yuliang Sun, Xiaoqian Lin, Jennifer Carlson Aske, Ping Ye, Casey Williams, Mark Abramovitz, Brian R. Leyland-Jones

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Triple-negative breast cancer (TNBC) has a poor prognosis because of limited treatment options. The combination of a poly ADP ribose polymerase (PARP) inhibitor with a DNA-damaging agent has shown promise in treating TNBC; however, not all patients respond to this combination. The Src protein kinase modulates multiple cancer cell properties and plays a key role in tumorigenic processes. However, Src inhibitors as single agents have shown limited effects in solid tumors. Here, we examined the antitumor effects of the Src inhibitor dasatinib, the PARP inhibitor veliparib, and the DNA-damaging agent carboplatin in TNBC models to try and identify the combination with the most clinical potential.

Methods

Dasatinib, veliparib and carboplatin were tested in TNBC cells in vitro and in xenograft tumors in vivo.

Results

Surprisingly, treatment with the combination of veliparib plus carboplatin led to an increase in Src phosphorylation. Importantly, dasatinib attenuated Src overexpression induced by veliparib plus carboplatin and further inhibited the downstream signaling of Src. In xenograft models, the triple combination of dasatinib with veliparib plus carboplatin showed greater tumor growth inhibitory effects compared with single agents or double combinations. No systemic toxicity was observed in mice treated with the triple combination.

Conclusions

This study emphasizes the merit of evaluating the triple combination therapy, dasatinib with veliparib plus carboplatin, in TNBC clinical trials.

Nur mit Berechtigung zugänglich

DeSantis C, Siegel R, Bandi P (2011) Jemal A (2011) Breast cancer statistics. CA Cancer J Clin 61(6):409–418PubMed

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics. CA Cancer J Clin 66(4):271–289PubMed

Qian XL, Zhang J, Li PZ, Lang RG, Li WD, Sun H, Liu FF, Guo XJ, Gu F, Fu L (2017) Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP). PLoS One 12(1):e0171169PubMedPubMedCentral

Sulaiman A, Wang L (2017) Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors. Oncotarget 8(68):113269–113281PubMedPubMedCentral

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13(11):674–690PubMedPubMedCentral

Lee A, Djamgoz MBA (2018) Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev 62:110–122PubMed

Roy R, Chun J, Powell SN (2011) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12(1):68–78PubMedPubMedCentral

Tahara M, Inoue T, Sato F, Miyakura Y, Horie H, Yasuda Y, Fujii H, Kotake K, Sugano K (2014) The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks. Mol Cancer Ther 13(5):1170–1180PubMed

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921PubMed

10.

Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244PubMed

11.

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A et al (2017) Olaparib for metastatic breast cancer in patients with a Germline BRCA Mutation. N Engl J Med 377(6):523–533PubMed

12.

De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N (2014) Doubling down on the PI3 K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia 16(1):43–72PubMedPubMedCentral

13.

Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC (2017) Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions. Curr Med Chem 24(15):1586–1606PubMedPubMedCentral

14.

Gampenrieder SP, Rinnerthaler G, Greil R (2017) SABCS 2016: systemic therapy for metastatic breast cancer. Memo 10(2):86–89PubMedPubMedCentral

15.

Rugo HS, Olopade OI, DeMichele A, Yau C, Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J et al (2016) Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 375(1):23–34PubMedPubMedCentral

16.

Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA, Corey SJ (2009) Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 101(1):38–47PubMedPubMedCentral

17.

Han MW, Ryu IS, Lee JC, Kim SH, Chang HW, Lee YS, Lee S, Kim SW, Kim SY (2018) Phosphorylation of PI3 K regulatory subunit p85 contributes to resistance against PI3 K inhibitors in radioresistant head and neck cancer. Oral Oncol 78:56–63PubMed

18.

Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzman M, Grueso J et al (2012) PI3 K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2(11):1036–1047PubMedPubMedCentral

19.

Tarpley M, Abdissa TT, Johnson GL, Scott JE (2014) Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines. Anticancer Res 34(4):1629–1635PubMedPubMedCentral

20.

Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ (2011) Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 17(21):6905–6913PubMed

21.

Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, Lee PS, Berchuck A, Lancaster J, Wenham RM (2012) A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clin Cancer Res 18(19):5489–5498PubMedPubMedCentral

22.

Sun Y, Dey N, Brammer M, De P, Leyland-Jones B (2013) Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumabrefractory breast cancer model. Cancer Chemother Pharmacol 72(4):733–745PubMed

23.

Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4(4):359–365PubMedPubMedCentral

24.

Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 5(12):3014–3022PubMed

25.

Lieser SA, Shaffer J, Adams JA (2006) SRC tail phosphorylation is limited by structural changes in the regulatory tyrosine kinase Csk. J Biol Chem 281(49):38004–38012PubMed

26.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M et al (2015) Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 22(1):58–73PubMed

27.

Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM (2012) STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res 18(1):127–139PubMed

28.

Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, Doyle B, McKay C, Heung MY, Oien KA et al (2010) Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 139(1):292–303PubMed

29.

Kamath AV, Wang J, Lee FY, Marathe PH (2008) Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 61(3):365–376PubMed

30.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/”triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105(3):319–326PubMed

31.

Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE (2017) Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget 8(61):103014–103031PubMedPubMedCentral

32.

Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE (2018) Src-mediated regulation of the PI3 K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis 7(2):23PubMedPubMedCentral

33.

Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA et al (2003) Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278(41):40057–40066PubMed

34.

Zhao Y, Scott A, Zhang P, Hao Y, Feng X, Somasundaram S, Khalil AM, Willis J, Wang Z (2017) Regulation of paxillin-p130-PI3 K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis. Oncotarget 8(30):48782–48793PubMed

35.

Skidmore CJ, Davies MI, Goodwin PM, Halldorsson H, Lewis PJ, Shall S, Zia’ee AA (1979) The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea. Eur J Biochem 101(1):135–142PubMed

36.

Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM et al (2014) Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med 3(6):1579–1594PubMedPubMedCentral

37.

Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppe JP, Heditsian D, Swigart-Brown L et al (2017) Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. BCR 19(1):107PubMed

38.

Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr (2010) Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 116(21):4980–4990PubMedPubMedCentral

39.

Chhibber-Goel J, Gaur A, Singhal V, Parakh N, Bhargava B, Sharma A (2016) The complex metabolism of trimethylamine in humans: endogenous and exogenous sources. Expert Rev Mol Med 18:e8PubMed

40.

Ribatti D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A (2016) Angiogenesis and antiangiogenesis in triple-negative breast cancer. Transl Oncol 9(5):453–457PubMedPubMedCentral

41.

Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, Marchio S, Aglietta M, Leone F (2012) Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther 11(7):1528–1538PubMed

42.

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER et al (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33(1):13–21PubMed

43.

Fleming JM, Miller TC, Meyer MJ, Ginsburg E, Vonderhaar BK (2010) Local regulation of human breast xenograft models. J Cell Physiol 224(3):795–806PubMedPubMedCentral

Titel: Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer
verfasst von: Yuliang Sun
Xiaoqian Lin
Jennifer Carlson Aske
Ping Ye
Casey Williams
Mark Abramovitz
Brian R. Leyland-Jones
Publikationsdatum: 20.09.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03962-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy

ABCC11 gene polymorphism as a potential predictive biomarker for an oral 5-fluorouracil derivative drug S-1 treatment in non-small cell lung cancer

Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate

BATF2 inhibits chemotherapy resistance by suppressing AP-1 in vincristine-resistant gastric cancer cells

A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors

Alternative dosing regimens for atezolizumab: right dose, wrong frequency

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie